News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Filed: 2026-09-09 AccNo: 0001646972-26-000054 Size: 163 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-09 AccNo: 0001627223-26-000027 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
– Reuters cites Iraqi port officials
Needham analyst Chris Pierce initiates coverage on Kodiak AI (NASDAQ:KDK) with a Buy rating and announces Price Target of $8.
– Reuters cites Iran Foreign Ministry statement
Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:TTAN) with a Buy and maintains $100 price target.
Scotts Miracle-Gro, Linde and Graphic Packaging are oversold materials stocks with RSI near 30, potentially offering undervalued buying opportunities.
SpaceX (SPCX) shares drop premarket amid a broader market slide. Get the latest analyst outlook, stock targets, and market updates.
ProLogium today announced a further deepening of its long-term strategic partnership with Kyushu Electric Power Co., Inc. (Kyushu Electric Power). Following ongoing collaboration across energy, next-generation batteries
BTIG analyst Nick Altmann reiterates ServiceTitan (NASDAQ:TTAN) with a Buy and maintains $110 price target.
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE:JKS), today announced that its board of directors (the "Board") has approved a proposal to change the Company's English name
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
The award supports the continuity and readiness of essential national security systems. It reinforces KBR’s strategic position as a trusted technology partner, combining deep mission expertise with an outcome-driven
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary
These awards expand AEVEX’s support for operational requirements across high‑priority mission areas. Under these efforts, AEVEX will deliver one‑way attack systems and provide associated engineering, development, and
BTIG analyst Nick Altmann reiterates Braze (NASDAQ:BRZE) with a Buy and maintains $35 price target.
FEDERAL PERMITTINGKilbourne remains on track under the FAST-41 permitting schedule, with all federal permits targeted for issuance by no later than August 2027.Section 404 (Clean Water Act): U.S. Army Corps of Engineers
HC Wainwright & Co. analyst Ananda Ghosh reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.
Anthropic researcher Evan Hubinger warned that AI could pose a significant risk to humanity within the next decade.
Filed: 2026-09-09 AccNo: 0000950142-26-002525 Size: 267 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other
SUNation (SUNE) stock jumped 26% premarket after merger partner Suniva raised $835M to fund major U.S. solar cell expansion.
Filed: 2026-09-09 AccNo: 0001628280-26-060996 Size: 147 KB Item 8.01: Other Events
Pelosi accused Trump-aligned Republicans of harming healthcare, military families and the economy, urging Democrats to vote them out in 2026 midterms.
Filed: 2026-09-09 AccNo: 0001062993-26-004859 Size: 646 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits